Rheumatoid Arthritis and Systemic Lupus Erythematosus As Immune Complex Diseases. Rheumatoid Arthritis and Systemic Lupus Erythematosus As Immune Complex Diseases.

Rheumatoid Arthritis and Systemic Lupus Erythematosus As Immune Complex Diseases‪.‬

Bulletin of the NYU Hospital for Joint Diseases 2009, July, 67, 3

    • 2,99 €
    • 2,99 €

Publisher Description

Rheumatology came late to the game of medical science and even later to immunology. From 1933 to 1948, our medical specialty was a descriptive art-we had no idea, in any meaningful way, what was going on. Cardiologists had their EKGs and digitalis, the endocrinologists had their thyroid tests and extracts, but rheumatologists seemed condemned to stand idly by to watch their patients turn into cripples or die in lupus crisis after one or another stopgap treatments. Oh yes, we had diathermy, gold salts, paraffin injections and, believe it or not, bee venom. We knew how to treat gout with colchicine, were just learning to give penicillin to prevent rheumatic fever, but by and large our treatment of joint disease or even systemic lupus erythematosus (SLE) was limited to aspirin, aspirin, and more aspirin. All that changed in the annus mirabilis of our field, 1948. At a staff meeting of the Mayo Clinic in January of 1948, Malcolm M. Hargraves described a strange kind of cell that formed in blood samples of patients with SLE.1 Before 1950, we could not really tell who had SLE and who did not; we had "no clue" as to why SLE was so often fatal. Hargraves had discovered what he called the "LE cell," which finally permitted us not only to make a diagnosis of the disease, but also told us what was going wrong with these poor women. The LE cell, it turned out over the years, is a white blood cell (a neutrophil) that has ingested the dying nucleus of another cell, against which lupus patients make antibodies. Complement was involved, acting as an opsonin. It also turned out that those antibodies against the nucleus and/or its constituents--the anti-DNA antibodies--were just the tip of an iceberg. SLE patients produce a dazzling number of antibodies, with their Fab regions directed against bits and pieces of their own cells. Their immune system recognizes such bits of "self" as if they were a microbe, a tad of "non-self that wants expunging. Hargrave's discovery of the LE cell sparked the study of autoimmunity and lifted rheumatology over the threshold of science. (1)

GENRE
Health & Well-Being
RELEASED
2009
1 July
LANGUAGE
EN
English
LENGTH
9
Pages
PUBLISHER
J. Michael Ryan Publishing Co.
SIZE
203.6
KB

More Books by Bulletin of the NYU Hospital for Joint Diseases

Simultaneous Bilateral Distal Biceps Tendon Rupture During a Preacher Curl Exercise: A Case Report (Clinical Report) Simultaneous Bilateral Distal Biceps Tendon Rupture During a Preacher Curl Exercise: A Case Report (Clinical Report)
2008
Predicting Response to TNF Antagonists in Rheumatoid Arthritis: The Promise of Pharmacogenetics Research Using Clinical Registries (Nyu Hospital for Joint Diseases Clinical Research Methodology Course) (Report) Predicting Response to TNF Antagonists in Rheumatoid Arthritis: The Promise of Pharmacogenetics Research Using Clinical Registries (Nyu Hospital for Joint Diseases Clinical Research Methodology Course) (Report)
2007
Resurfacing Versus Conventional Total Hip Arthroplasty: Review of Comparative Clinical and Basic Science Studies (Clinical Report) Resurfacing Versus Conventional Total Hip Arthroplasty: Review of Comparative Clinical and Basic Science Studies (Clinical Report)
2009
A Comparison of Total Hip Resurfacing and Total Hip Arthroplasty: Patients and Outcomes. A Comparison of Total Hip Resurfacing and Total Hip Arthroplasty: Patients and Outcomes.
2009
Resurfacing Matched to Standard Total Hip Arthroplasty by Preoperative Activity Levels: A Comparison of Postoperative Outcomes (Clinical Report) Resurfacing Matched to Standard Total Hip Arthroplasty by Preoperative Activity Levels: A Comparison of Postoperative Outcomes (Clinical Report)
2009
The COX 2 Selective Inhibitors: What the Newspapers Have Not Told You (Cyclooxygenase-2) (Clinical Report) The COX 2 Selective Inhibitors: What the Newspapers Have Not Told You (Cyclooxygenase-2) (Clinical Report)
2007